argenx SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARGX research report →
About the company
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions.
- CEO
- Timothy Van Hauwermeiren
- IPO
- 2017
- Employees
- 1,599
- HQ
- Amsterdam, NL
Price Chart
- Market Cap
- $58.15B
- P/E
- 51.71
- P/S
- 17.41
- P/B
- 7.97
- EV/EBITDA
- 52.22
- Div Yield
- 0.00%
- Gross Margin
- 89.00%
- Op Margin
- 25.64%
- Net Margin
- 33.42%
- ROE
- 16.82%
- ROIC
- 11.74%
- Revenue
- $4.15B · 89.64%
- Net Income
- $1.29B · 55.10%
- EPS
- $21.14 · 51.87%
- Op Income
- $1.05B
- FCF YoY
- 658.96%
- 52W High
- $953.58
- 52W Low
- $536.02
- 50D MA
- $836.25
- 200D MA
- $817.75
- Beta
- -0.03
- Avg Volume
- 341.97K
Get TickerSpark's AI analysis on ARGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ARGX coverage
Recent articles, reports, and earnings notes.
No research on ARGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ARGX report →Similar companies
Peers in the same neighborhood.